Inhibition of Intimal Thickening By PRH (Proline-Rich Homeodomain) in Mice.
endothelial cell
mice
monocyte
phenotype
saphenous vein
smooth muscle
Journal
Arteriosclerosis, thrombosis, and vascular biology
ISSN: 1524-4636
Titre abrégé: Arterioscler Thromb Vasc Biol
Pays: United States
ID NLM: 9505803
Informations de publication
Date de publication:
03 2023
03 2023
Historique:
pubmed:
27
1
2023
medline:
25
2
2023
entrez:
26
1
2023
Statut:
ppublish
Résumé
Late vein graft failure is caused by intimal thickening resulting from endothelial cell (EC) damage and inflammation which promotes vascular smooth muscle cell (VSMC) dedifferentiation, migration, and proliferation. Nonphosphorylatable PRH (proline-rich homeodomain) S163C:S177C offers enhanced stability and sustained antimitotic effect. Therefore, we investigated whether adenovirus-delivered PRH S163C:S177C protein attenuates intimal thickening via VSMC phenotype modification without detrimental effects on ECs. PRH S163C:S177C was expressed in vitro (human saphenous vein-VSMCs and human saphenous vein-ECs) and in vivo (ligated mouse carotid arteries) by adenoviruses. Proliferation, migration, and apoptosis were quantified and phenotype was assessed using Western blotting for contractile filament proteins and collagen gel contraction. EC inflammation was quantified using VCAM (vascular cell adhesion protein)-1, ICAM (intercellular adhesion molecule)-1, interleukin-6, and monocyte chemotactic factor-1 measurement and monocyte adhesion. Next Generation Sequencing was utilized to identify novel downstream mediators of PRH action and these and intimal thickening were investigated in vivo. PRH S163C:S177C inhibited proliferation, migration, and apoptosis and promoted contractile phenotype (enhanced contractile filament proteins and collagen gel contraction) compared with virus control in human saphenous vein-VSMCs. PRH S163C:S177C expression in human saphenous vein-ECs significantly reduced apoptosis, without affecting cell proliferation and migration, while reducing TNF (tumor necrosis factor)-α-induced VCAM-1 and ICAM-1 and monocyte adhesion and suppressing interleukin-6 and monocyte chemotactic factor-1 protein levels. PRH S163C:S177C expression in ligated murine carotid arteries significantly impaired carotid artery ligation-induced neointimal proliferation and thickening without reducing endothelial coverage. Next Generation Sequencing revealed STAT-1 (signal transducer and activator of transcription 1) and HDAC-9 (histone deacetylase 9) as mediators of PRH action and was supported by in vitro and in vivo analyses. We observed PRH S163C:S177C attenuated VSMC proliferation, and migration and enhanced VSMC differentiation at least in part via STAT-1 and HDAC-9 signaling while promoting endothelial repair and anti-inflammatory properties. These findings highlight the potential for PRH S163C:S177C to preserve endothelial function whilst suppressing intimal thickening, and reducing late vein graft failure.
Sections du résumé
BACKGROUND
Late vein graft failure is caused by intimal thickening resulting from endothelial cell (EC) damage and inflammation which promotes vascular smooth muscle cell (VSMC) dedifferentiation, migration, and proliferation. Nonphosphorylatable PRH (proline-rich homeodomain) S163C:S177C offers enhanced stability and sustained antimitotic effect. Therefore, we investigated whether adenovirus-delivered PRH S163C:S177C protein attenuates intimal thickening via VSMC phenotype modification without detrimental effects on ECs.
METHODS
PRH S163C:S177C was expressed in vitro (human saphenous vein-VSMCs and human saphenous vein-ECs) and in vivo (ligated mouse carotid arteries) by adenoviruses. Proliferation, migration, and apoptosis were quantified and phenotype was assessed using Western blotting for contractile filament proteins and collagen gel contraction. EC inflammation was quantified using VCAM (vascular cell adhesion protein)-1, ICAM (intercellular adhesion molecule)-1, interleukin-6, and monocyte chemotactic factor-1 measurement and monocyte adhesion. Next Generation Sequencing was utilized to identify novel downstream mediators of PRH action and these and intimal thickening were investigated in vivo.
RESULTS
PRH S163C:S177C inhibited proliferation, migration, and apoptosis and promoted contractile phenotype (enhanced contractile filament proteins and collagen gel contraction) compared with virus control in human saphenous vein-VSMCs. PRH S163C:S177C expression in human saphenous vein-ECs significantly reduced apoptosis, without affecting cell proliferation and migration, while reducing TNF (tumor necrosis factor)-α-induced VCAM-1 and ICAM-1 and monocyte adhesion and suppressing interleukin-6 and monocyte chemotactic factor-1 protein levels. PRH S163C:S177C expression in ligated murine carotid arteries significantly impaired carotid artery ligation-induced neointimal proliferation and thickening without reducing endothelial coverage. Next Generation Sequencing revealed STAT-1 (signal transducer and activator of transcription 1) and HDAC-9 (histone deacetylase 9) as mediators of PRH action and was supported by in vitro and in vivo analyses.
CONCLUSIONS
We observed PRH S163C:S177C attenuated VSMC proliferation, and migration and enhanced VSMC differentiation at least in part via STAT-1 and HDAC-9 signaling while promoting endothelial repair and anti-inflammatory properties. These findings highlight the potential for PRH S163C:S177C to preserve endothelial function whilst suppressing intimal thickening, and reducing late vein graft failure.
Identifiants
pubmed: 36700427
doi: 10.1161/ATVBAHA.122.318367
pmc: PMC9944393
doi:
Substances chimiques
Interleukin-6
0
Chemotactic Factors
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
456-473Subventions
Organisme : British Heart Foundation
ID : FS/17/46/33121
Pays : United Kingdom
Organisme : British Heart Foundation
ID : FS/18/1/33234
Pays : United Kingdom
Références
Gene Ther. 2012 Jun;19(6):630-6
pubmed: 22456326
Circ Res. 2001 Jul 6;89(1):71-6
pubmed: 11440980
J R Soc Interface. 2014 Aug 6;11(97):20140330
pubmed: 24898022
Nat Genet. 2017 Sep;49(9):1385-1391
pubmed: 28714975
Atherosclerosis. 2017 Oct;265:266-274
pubmed: 28865843
BMJ Open Sci. 2020 Jul 20;4(1):e100115
pubmed: 34095516
Physiol Rev. 2011 Jan;91(1):327-87
pubmed: 21248169
Am J Physiol Heart Circ Physiol. 2007 Jun;292(6):H2935-43
pubmed: 17293493
J Vasc Surg. 2010 Nov;52(5):1301-9
pubmed: 20630685
J Cell Commun Signal. 2018 Sep;12(3):529-537
pubmed: 29185213
Circulation. 2011 Sep 13;124(11 Suppl):S135-42
pubmed: 21911803
Arterioscler Thromb Vasc Biol. 2011 Feb;31(2):384-91
pubmed: 21127291
Gastroenterology. 1999 Apr;116(4):874-83
pubmed: 10092309
Oncogene. 2014 Dec 4;33(49):5592-600
pubmed: 24240683
Nucleic Acids Res. 2009 Jun;37(10):3288-300
pubmed: 19324893
Apoptosis. 2017 Aug;22(8):1001-1012
pubmed: 28601953
Proc Natl Acad Sci U S A. 1994 May 24;91(11):4678-82
pubmed: 8197118
Circulation. 2011 Jul 19;124(3):273-5
pubmed: 21768550
Vascul Pharmacol. 2017 Dec;99:34-44
pubmed: 28927755
Arterioscler Thromb Vasc Biol. 2019 Jul;39(7):1351-1368
pubmed: 31144989
Circulation. 1985 Dec;72(6 Pt 2):V71-8
pubmed: 3905060
Nat Genet. 2019 Nov;51(11):1580-1587
pubmed: 31659325
Ann Thorac Surg. 2004 May;77(5):1575-9
pubmed: 15111145
Ann Thorac Surg. 2009 May;87(5):1386-91
pubmed: 19379870
Biochem J. 2008 Jun 15;412(3):399-413
pubmed: 18498250
J Pharmacol Sci. 2003 Mar;91(3):172-6
pubmed: 12686737
Arterioscler Thromb Vasc Biol. 2004 Sep;24(9):1602-7
pubmed: 15242862
J Am Coll Cardiol. 1996 Sep;28(3):616-26
pubmed: 8772748
Stroke. 2019 Oct;50(10):2651-2660
pubmed: 31500558
JACC Cardiovasc Interv. 2018 Oct 22;11(20):2072-2080
pubmed: 30268874
Mol Ther Methods Clin Dev. 2017 May 04;5:191-199
pubmed: 28540322
Arterioscler Thromb Vasc Biol. 2012 Oct;32(10):2418-26
pubmed: 22904274
ISRN Minim Invasive Surg. 2013 Mar 31;2013:
pubmed: 23762781
Arterioscler Thromb Vasc Biol. 2016 Jul;36(7):1417-24
pubmed: 27199447
Med Oncol. 2012 Jun;29(2):1059-67
pubmed: 21656028
Arterioscler Thromb Vasc Biol. 2007 Sep;27(9):1870-6
pubmed: 17585068
Am J Pathol. 1998 Oct;153(4):1301-10
pubmed: 9777962
Circ Res. 2020 Aug 28;127(6):811-823
pubmed: 32546048
Trends Immunol. 2018 Feb;39(2):82-85
pubmed: 29307449
N Engl J Med. 1986 Jan 2;314(1):1-6
pubmed: 3484393
Stroke. 2013 May;44(5):1220-5
pubmed: 23449258
Tissue Eng Part B Rev. 2010 Oct;16(5):467-91
pubmed: 20334504
Expert Rev Cardiovasc Ther. 2010 Apr;8(4):545-56
pubmed: 20397828
Nat Genet. 2018 Apr;50(4):524-537
pubmed: 29531354
Front Biosci (Landmark Ed). 2009 Jan 01;14(7):2522-45
pubmed: 19273217
Leuk Res. 2013 Sep;37(9):986-94
pubmed: 23787174
Sci Rep. 2017 Aug 1;7(1):6989
pubmed: 28765576